FibroGen plans to implement a significant cost reduction effort in the U.S. with the intent to extend our cash runway into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FGEN:
- FibroGen Tanks after Phase 3 Data in Pulmonary Fibrosis Disappoints
- FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
- FibroGen put volume heavy and directionally bearish
- FGEN Slides after DMD Candidate Fails In Phase 3 Trial
- FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy